Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Histone deacetylase inhibition decreases proliferation and potentiates the effect of ionizing radiation in atypical teratoid/rhabdoid tumor cells.

Knipstein JA, Birks DK, Donson AM, Alimova I, Foreman NK, Vibhakar R.

Neuro Oncol. 2012 Feb;14(2):175-83. doi: 10.1093/neuonc/nor208. Epub 2011 Dec 8.

2.

Histone deacetylase inhibitors induce cell death and enhance the susceptibility to ionizing radiation, etoposide, and TRAIL in medulloblastoma cells.

Sonnemann J, Kumar KS, Heesch S, Müller C, Hartwig C, Maass M, Bader P, Beck JF.

Int J Oncol. 2006 Mar;28(3):755-66.

PMID:
16465382
3.

Sensitization to gamma-irradiation-induced cell cycle arrest and apoptosis by the histone deacetylase inhibitor trichostatin A in non-small cell lung cancer (NSCLC) cells.

Zhang F, Zhang T, Teng ZH, Zhang R, Wang JB, Mei QB.

Cancer Biol Ther. 2009 May;8(9):823-31. Epub 2009 May 10.

PMID:
19270532
4.

Inhibitors of histone deacetylases as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood.

Furchert SE, Lanvers-Kaminsky C, Juürgens H, Jung M, Loidl A, Frühwald MC.

Int J Cancer. 2007 Apr 15;120(8):1787-94.

5.

Histone deacetylase inhibitors sensitize human non-small cell lung cancer cells to ionizing radiation through acetyl p53-mediated c-myc down-regulation.

Seo SK, Jin HO, Woo SH, Kim YS, An S, Lee JH, Hong SI, Lee KH, Choe TB, Park IC.

J Thorac Oncol. 2011 Aug;6(8):1313-9. doi: 10.1097/JTO.0b013e318220caff.

6.

Profiling pathway-specific novel therapeutics in preclinical assessment for central nervous system atypical teratoid rhabdoid tumors (CNS ATRT): favorable activity of targeting EGFR- ErbB2 signaling with lapatinib.

Singh A, Lun X, Jayanthan A, Obaid H, Ruan Y, Strother D, Chi SN, Smith A, Forsyth P, Narendran A.

Mol Oncol. 2013 Jun;7(3):497-512. doi: 10.1016/j.molonc.2013.01.001. Epub 2013 Jan 11.

7.

Inhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in atypical rhabdoid teratoid tumor cells.

Alimova I, Birks DK, Harris PS, Knipstein JA, Venkataraman S, Marquez VE, Foreman NK, Vibhakar R.

Neuro Oncol. 2013 Feb;15(2):149-60. doi: 10.1093/neuonc/nos285. Epub 2012 Nov 28.

8.

Resveratrol-induced apoptosis and increased radiosensitivity in CD133-positive cells derived from atypical teratoid/rhabdoid tumor.

Kao CL, Huang PI, Tsai PH, Tsai ML, Lo JF, Lee YY, Chen YJ, Chen YW, Chiou SH.

Int J Radiat Oncol Biol Phys. 2009 May 1;74(1):219-28. doi: 10.1016/j.ijrobp.2008.12.035.

PMID:
19362240
9.

Histone deacetylase inhibitors induce cell death and enhance the apoptosis-inducing activity of TRAIL in Ewing's sarcoma cells.

Sonnemann J, Dreyer L, Hartwig M, Palani CD, Hong le TT, Klier U, Bröker B, Völker U, Beck JF.

J Cancer Res Clin Oncol. 2007 Nov;133(11):847-58. Epub 2007 May 8.

PMID:
17486365
11.

In vivo efficacy of the histone deacetylase inhibitor suberoylanilide hydroxamic acid in combination with radiotherapy in a malignant rhabdoid tumor mouse model.

Thiemann M, Oertel S, Ehemann V, Weichert W, Stenzinger A, Bischof M, Weber KJ, Perez RL, Haberkorn U, Kulozik AE, Debus J, Huber PE, Battmann C.

Radiat Oncol. 2012 Mar 29;7:52. doi: 10.1186/1748-717X-7-52.

12.

Targeting Aurora Kinase A enhances radiation sensitivity of atypical teratoid rhabdoid tumor cells.

Venkataraman S, Alimova I, Tello T, Harris PS, Knipstein JA, Donson AM, Foreman NK, Liu AK, Vibhakar R.

J Neurooncol. 2012 May;107(3):517-26. doi: 10.1007/s11060-011-0795-y. Epub 2012 Jan 15.

13.

Atypical teratoid/rhabdoid tumors (ATRT): improved survival in children 3 years of age and older with radiation therapy and high-dose alkylator-based chemotherapy.

Tekautz TM, Fuller CE, Blaney S, Fouladi M, Broniscer A, Merchant TE, Krasin M, Dalton J, Hale G, Kun LE, Wallace D, Gilbertson RJ, Gajjar A.

J Clin Oncol. 2005 Mar 1;23(7):1491-9.

PMID:
15735125
14.

Histone deacetylase inhibitors promote osteoblast maturation.

Schroeder TM, Westendorf JJ.

J Bone Miner Res. 2005 Dec;20(12):2254-63. Epub 2005 Aug 8.

15.

Atypical teratoid rhabdoid tumor: improved long-term survival with an intensive multimodal therapy and delayed radiotherapy. The Medical University of Vienna Experience 1992-2012.

Slavc I, Chocholous M, Leiss U, Haberler C, Peyrl A, Azizi AA, Dieckmann K, Woehrer A, Peters C, Widhalm G, Dorfer C, Czech T.

Cancer Med. 2014 Feb;3(1):91-100. doi: 10.1002/cam4.161. Epub 2013 Dec 11.

16.

The paradox of histone deacetylase inhibitor-mediated modulation of cellular responses to radiation.

Karagiannis TC, El-Osta A.

Cell Cycle. 2006 Feb;5(3):288-95. Epub 2006 Feb 17. Review.

PMID:
16418577
17.

Histone deacetylases expression in atypical teratoid rhabdoid tumors.

Sredni ST, Halpern AL, Hamm CA, Bonaldo Mde F, Tomita T.

Childs Nerv Syst. 2013 Jan;29(1):5-9. doi: 10.1007/s00381-012-1965-8. Epub 2012 Nov 10.

PMID:
23143003
19.

Modulation of radiation response by histone deacetylase inhibition.

Chinnaiyan P, Vallabhaneni G, Armstrong E, Huang SM, Harari PM.

Int J Radiat Oncol Biol Phys. 2005 May 1;62(1):223-9.

PMID:
15850925
20.

HDAC inhibitor-mediated radiosensitization in human carcinoma cells: a general phenomenon?

Kim IA, Kim IH, Kim HJ, Chie EK, Kim JS.

J Radiat Res. 2010;51(3):257-63.

Supplemental Content

Support Center